Medicalsystem Biotechnology Co., Ltd. (300439.SZ)
CNY 11.16
(-0.36%)
CNY 11.16
(-0.36%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 663.08 Million | 564.66 Million | 515.48 Million | 912.07 Million | 601.17 Million | 418.8 Million |
| Net Income | 256.55 Million | 205.2 Million | 190.15 Million | 293.56 Million | -576.62 Million | 252.95 Million |
| Depreciation & Amortization | 184.73 Million | 191.67 Million | 194.82 Million | 173.51 Million | 161.48 Million | 150.32 Million |
| Deferred income taxes | 2.87 Million | -10.24 Million | -8.6 Million | 39.51 Million | -11.6 Million | 16.18 Million |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 200.18 Million | 71.61 Million | 18.59 Million | 496 Million | 83.47 Million | -109.63 Million |
| Other non-cash items | 204.6 Million | 96.17 Million | 111.91 Million | -51.01 Million | 932.84 Million | 125.15 Million |
| Investing Cash Flow | -200.78 Million | -232.49 Million | -187.55 Million | -253.01 Million | -288.55 Million | -451.13 Million |
| Investments in PPE | -280.36 Million | -303.13 Million | -201.81 Million | -383.43 Million | -363.2 Million | -446.21 Million |
| Acquisitions | 77.96 Million | 33.54 Million | 5.2 Million | 13.41 Million | 17.01 Million | -172.38 Million |
| Investment purchases | -272.7 Million | -280.4 Million | -300.6 Million | 26.46 Million | -164.6 Million | -843.31 Million |
| Sales/Maturities of investments | 291.5 Million | 308.66 Million | 276.61 Million | 74.23 Million | 185.85 Million | 1.01 Billion |
| Other Investing Activities | -17.17 Million | 8.83 Million | 33.04 Million | 16.3 Million | 36.37 Million | -4.52 Million |
| Financing Cash Flow | -294.38 Million | -221.07 Million | 24.2 Million | -774.26 Million | -290.75 Million | 66.66 Million |
| Debt repayment | -228.03 Million | -361.89 Million | -864.06 Million | -1.57 Billion | -1.86 Billion | -1.38 Billion |
| Dividends payments | -40.21 Million | -36.38 Million | -60.02 Million | -125.37 Million | -50.21 Million | -116.39 Million |
| Common Stock Repurchased | - | - | - | -27.87 Million | -13.45 Million | -6.13 Million |
| Common Stock Issuance | - | - | - | -900 Thousand | 13.45 Million | - |
| Other Financing Activities | -7.56 Million | 191.52 Million | 979.65 Million | 957.25 Million | 1.7 Billion | 1.57 Billion |
| Accounts receivables | 206.65 Million | -76.75 Million | -147.17 Million | 372.34 Million | 125.27 Million | -265.5 Million |
| Accounts payables | 34.97 Million | 179.32 Million | 159.07 Million | 2.37 Million | 14.36 Million | 85.82 Million |
| Inventory | -58.01 Million | -20.71 Million | 15.31 Million | 81.76 Million | -44.55 Million | 53.86 Million |
| Other working capital | 16.56 Million | -10.24 Million | -8.6 Million | 39.51 Million | -11.6 Million | -163.49 Million |
| Cash at beginning of period | 806.41 Million | 674.33 Million | 321.27 Million | 436.58 Million | 415.51 Million | 378.84 Million |
| Cash at end of period | 958.88 Million | 783.85 Million | 674.33 Million | 321.27 Million | 436.58 Million | 415.51 Million |
| Capital Expenditure | -280.36 Million | -303.13 Million | -201.81 Million | -383.43 Million | -363.2 Million | -446.21 Million |
| Effect of forex changes on cash | 544.98 Thousand | -1.58 Million | 933.95 Thousand | -99.46 Thousand | -798.25 Thousand | 2.34 Million |
| Net cash flow / Change in cash | 152.46 Million | 109.51 Million | 353.05 Million | -115.3 Million | 21.06 Million | 36.67 Million |
| Free Cash Flow | 382.72 Million | 261.53 Million | 313.66 Million | 528.64 Million | 237.96 Million | -27.41 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 45.9 Million | 99.36 Million | 79.09 Million | 256.55 Million | 26.59 Million | 55.09 Million |
| Depreciation & Amortization | - | 43.66 Million | 43.66 Million | 184.73 Million | 43.01 Million | -89.51 Million |
| Deferred income taxes | - | - | - | 2.87 Million | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | - | 200.18 Million | 165.2 Million | -100.87 Million |
| Other non-cash items | -36.29 Million | 36.18 Million | -69.94 Million | 204.6 Million | 42.75 Million | 259.87 Million |
| Investing Cash Flow | -134.21 Million | -121.13 Million | -138.27 Million | -200.78 Million | -102.96 Million | -81.64 Million |
| Investments in PPE | -68.42 Million | -22.98 Million | -87.43 Million | -280.36 Million | -63.2 Million | -91.03 Million |
| Acquisitions | -72.8 Thousand | 4.42 Million | 13.16 Million | 77.96 Million | 31.34 Million | 10.4 Million |
| Investment purchases | -392 Million | -232 Million | -70 Million | -272.7 Million | -105.41 Million | -1.01 Million |
| Sales/Maturities of investments | 326 Million | 113.3 Million | 6 Million | 291.5 Million | 51.5 Million | - |
| Other Investing Activities | 276.65 Thousand | 16.12 Million | -50.83 Million | -17.17 Million | -17.18 Million | 9500.00 |
| Financing Cash Flow | 8.67 Million | -66.33 Million | -20.43 Million | -294.38 Million | -130.1 Million | -31.41 Million |
| Debt repayment | - | -7.04 Million | -20 Million | -228.03 Million | -112.04 Million | -10 Million |
| Dividends payments | -686.86 Thousand | -51.78 Million | -432.32 Thousand | -40.21 Million | -40.21 Million | -18.31 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 9.36 Million | -51.78 Million | -432.32 Thousand | -7.56 Million | 40.72 Million | -3.09 Million |
| Accounts receivables | - | - | - | 206.65 Million | 206.65 Million | -100.33 Million |
| Accounts payables | - | - | - | 34.97 Million | - | 1.04 Million |
| Inventory | - | - | - | -58.01 Million | -58.01 Million | -537.47 Thousand |
| Other working capital | - | - | - | 16.56 Million | 16.56 Million | -1.04 Million |
| Cash at beginning of period | 706.59 Million | 802.77 Million | 952.32 Million | 806.41 Million | 929.31 Million | 894.88 Million |
| Cash at end of period | 590.8 Million | 706.59 Million | 802.77 Million | 958.88 Million | 958.88 Million | 907.05 Million |
| Capital Expenditure | -68.42 Million | -22.98 Million | -87.43 Million | -280.36 Million | -63.2 Million | -91.03 Million |
| Effect of forex changes on cash | 1.14 Million | -724.75 | 7499.50 | 544.98 Thousand | 762.04 Thousand | 653.56 Thousand |
| Net cash flow / Change in cash | -115.79 Million | -96.18 Million | -149.54 Million | 152.46 Million | 29.56 Million | 12.17 Million |
| Free Cash Flow | -58.82 Million | 68.9 Million | -78.28 Million | 382.72 Million | 214.36 Million | 33.53 Million |
LUV
SYUP
IQAIF
VITFF
600148
CTM